The pneumococcal vaccine age dropped from 65 to 50

Before October 2024, a single dose of **15-, 20- or 21-valent pneumococcal
conjugate vaccine (PCV)** was recommended for **adults aged 19–64 with risk
conditions**, and for all adults aged 65 and over.

**On 23 October 2024, the Advisory Committee on Immunization Practices
recommended a single dose of PCV for all adults aged 50 and over** who are
PCV-naïve or whose vaccination history is unknown.

The risk-based recommendation for adults aged 19–49 is unchanged.

What actually changed

The age-based recommendation moved from 65 to 50. Everything else
stayed where it was.

Why this band

**The expanded recommendation is expected to improve pneumococcal disease
prevention in adults aged 50–64, particularly among demographic groups
experiencing higher disease rates.**

That final clause is the reasoning. A risk-based recommendation only reaches
people whose risk condition has been diagnosed and recorded, and who then get
offered the vaccine. Where rates of pneumococcal disease are highest, access
to the diagnosis and the offer is often lowest — so the risk-based approach
misses the people who need it most.

An age-based rule removes that filter. Everyone at 50 qualifies, whatever is
or is not on their chart.

*Source: Kobayashi M, Leidner AJ, Gierke R, et al. Expanded Recommendations
for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years:
Recommendations of the Advisory Committee on Immunization Practices — United
States, 2024. MMWR, Centers for Disease Control and Prevention.*